

# Paul A Townsend

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11420154/publications.pdf>

Version: 2024-02-01

75  
papers

3,907  
citations

117625

34  
h-index

133252

59  
g-index

80  
all docs

80  
docs citations

80  
times ranked

6991  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 755-761.	3.9	14
2	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature Genetics</i> , 2021, 53, 65-75.	21.4	264
3	Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 532-541.	3.9	16
4	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. <i>Nature Communications</i> , 2021, 12, 1236.	12.8	40
5	Cathepsin S Cleaves BAX as a Novel and Therapeutically Important Regulatory Mechanism for Apoptosis. <i>Pharmaceutics</i> , 2021, 13, 339.	4.5	7
6	Intrinsically Connected: Therapeutically Targeting the Cathepsin Proteases and the Bcl-2 Family of Protein Substrates as Co-regulators of Apoptosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4669.	4.1	9
7	Integrative p53, micro-RNA and Cathepsin Protease Co-Regulatory Expression Networks in Cancer. <i>Cancers</i> , 2020, 12, 3454.	3.7	6
8	Making Connections: p53 and the Cathepsin Proteases as Co-Regulators of Cancer and Apoptosis. <i>Cancers</i> , 2020, 12, 3476.	3.7	11
9	An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer risk. <i>Nature Communications</i> , 2020, 11, 3905.	12.8	28
10	The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. <i>Cancers</i> , 2020, 12, 3254.	3.7	16
11	Lost or Forgotten: The nuclear cathepsin protein isoforms in cancer. <i>Cancer Letters</i> , 2019, 462, 43-50.	7.2	24
12	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019, 10, 431.	12.8	88
13	Cysteine Cathepsin Protease Inhibition: An update on its Diagnostic, Prognostic and Therapeutic Potential in Cancer. <i>Pharmaceutics</i> , 2019, 12, 87.	3.8	41
14	Germline variation at 8q24 and prostate cancer risk in men of European ancestry. <i>Nature Communications</i> , 2018, 9, 4616.	12.8	43
15	Candidate plasma biomarkers for predicting ascending aortic aneurysm in bicuspid aortic valve disease. <i>Journal of Cardiothoracic Surgery</i> , 2018, 13, 76.	1.1	6
16	Increased circulating resistin levels in early-onset breast cancer patients of normal body mass index correlate with lymph node negative involvement and longer disease free survival: a multi-center POSH cohort serum proteomics study. <i>Breast Cancer Research</i> , 2018, 20, 19.	5.0	18
17	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. <i>Nature Genetics</i> , 2018, 50, 928-936.	21.4	652
18	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. <i>Nature Communications</i> , 2018, 9, 2256.	12.8	88

#	ARTICLE	IF	CITATIONS
19	The effects of restricted glycolysis on stem-cell like characteristics of breast cancer cells. <i>Oncotarget</i> , 2018, 9, 23274-23288.	1.8	9
20	Urocortin suppresses endometrial cancer cell migration via CRFR2 and its system components are differentially modulated by estrogen. <i>Cancer Medicine</i> , 2017, 6, 408-415.	2.8	11
21	Integrated Cellular and Plasma Proteomics of Contrasting B-cell Cancers Reveals Common, Unique and Systemic Signatures. <i>Molecular and Cellular Proteomics</i> , 2017, 16, 386-406.	3.8	15
22	Regulation of osteoblast development by Bcl-2-associated athanogene-1 (BAG-1). <i>Scientific Reports</i> , 2016, 6, 33504.	3.3	6
23	Role of stress-activated OCT4A in the cell fate decisions of embryonal carcinoma cells treated with etoposide. <i>Cell Cycle</i> , 2015, 14, 2969-2984.	2.6	29
24	Clinical proteomics and breast cancer. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2015, 13, 271-278.	1.8	28
25	Targeting tumor-initiating cells: Eliminating anabolic cancer stem cells with inhibitors of protein synthesis or by mimicking caloric restriction. <i>Oncotarget</i> , 2015, 6, 4585-4601.	1.8	55
26	Annexin A3 is a mammary marker and a potential neoplastic breast cell therapeutic target. <i>Oncotarget</i> , 2015, 6, 21421-21427.	1.8	9
27	Whole Serum 3D LC-nESI-FTMS Quantitative Proteomics Reveals Sexual Dimorphism in the Milieu Intérieur of Overweight and Obese Adults. <i>Journal of Proteome Research</i> , 2014, 13, 5094-5105.	3.7	49
28	Heart failure: The pivotal role of histone deacetylases. <i>International Journal of Biochemistry and Cell Biology</i> , 2013, 45, 448-453.	2.8	11
29	Pharmacoproteomic Study of the Natural Product Ebenfuran III in DU-145 Prostate Cancer Cells: The Quantitative and Temporal Interrogation of Chemically Induced Cell Death at the Protein Level. <i>Journal of Proteome Research</i> , 2013, 12, 1591-1603.	3.7	10
30	The Shotgun Proteomic Study of the Human ThinPrep Cervical Smear Using iTRAQ Mass-Tagging and 2D LC-FT-Orbitrap-MS: The Detection of the Human Papillomavirus at the Protein Level. <i>Journal of Proteome Research</i> , 2013, 12, 2078-2089.	3.7	33
31	Regulation of Myocardial Interleukin-6 Expression by p53 and STAT1. <i>Journal of Interferon and Cytokine Research</i> , 2013, 33, 542-548.	1.2	13
32	Proteomics of human prostate cancer biospecimens: the global, systems-wide perspective for Protein markers with potential clinical utility. <i>Expert Review of Proteomics</i> , 2013, 10, 337-354.	3.0	7
33	DNA damage causes TP53-dependent coupling of self-renewal and senescence pathways in embryonal carcinoma cells. <i>Cell Cycle</i> , 2013, 12, 430-441.	2.6	37
34	Role of STAT1 in the breast. <i>Jak-stat</i> , 2012, 1, 197-199.	2.2	6
35	The NF- $\kappa$ B Subunit c-Rel Stimulates Cardiac Hypertrophy and Fibrosis. <i>American Journal of Pathology</i> , 2012, 180, 929-939.	3.8	65
36	Transgenic overexpression of HSP56 does not result in cardiac hypertrophy nor protect from ischaemia/reperfusion injury. <i>International Journal of Biochemistry and Cell Biology</i> , 2011, 43, 74-79.	2.8	2

#	ARTICLE	IF	CITATIONS
37	Regulating the genome surveillance system: miRNAs and the p53 super family. Apoptosis: an International Journal on Programmed Cell Death, 2010, 15, 541-552.	4.9	22
38	Dr. Trudy (Helmtrud) Roach (17.09.1944â€“28.04.2010). Apoptosis: an International Journal on Programmed Cell Death, 2010, 15, 1423-1424.	4.9	0
39	STAT3 modulates the DNA damage response pathway. International Journal of Experimental Pathology, 2010, 91, 506-514.	1.3	80
40	New targets of urocortin-mediated cardioprotection. Journal of Molecular Endocrinology, 2010, 45, 69-85.	2.5	36
41	What Causes a Broken Heart? Molecular Insights into Heart Failure. International Review of Cell and Molecular Biology, 2010, 284, 113-179.	3.2	67
42	Histone Deacetylase Inhibitors: New Promise in the Treatment of Immune and Inflammatory Diseases. Current Drug Targets, 2010, 999, 1-9.	2.1	1
43	Thioflavin S (NSC71948) Interferes with Bcl-2-Associated Athanogene (BAG-1)-Mediated Protein-Protein Interactions. Journal of Pharmacology and Experimental Therapeutics, 2009, 331, 680-689.	2.5	30
44	The powerful cardioprotective effects of urocortin and the corticotropin releasing hormone (CRH) family. Biochemical Pharmacology, 2009, 77, 141-150.	4.4	46
45	Short peptides derived from the BAG-1 C-terminus inhibit the interaction between BAG-1 and HSC70 and decrease breast cancer cell growth. FEBS Letters, 2009, 583, 3405-3411.	2.8	17
46	SELDI-TOF MS Proteomics in Breast Cancer. Clinical Proteomics, 2009, 5, 133-147.	2.1	4
47	STAT3 deletion sensitizes cells to oxidative stress. Biochemical and Biophysical Research Communications, 2009, 385, 324-329.	2.1	53
48	Mechanisms of action and clinical implications of cardiac urocortin: A journey from the heart to the systemic circulation, with a stopover in the mitochondria. International Journal of Cardiology, 2009, 137, 189-194.	1.7	9
49	Amino Acid Supplementation Differentially Modulates STAT1 and STAT3 Activation in the Myocardium Exposed to Ischemia/Reperfusion Injury. American Journal of Cardiology, 2008, 101, S63-S68.	1.6	12
50	SELDI-TOF proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression. Breast Cancer Research, 2008, 10, 107.	5.0	17
51	Molecular regulation of cardiac hypertrophy. International Journal of Biochemistry and Cell Biology, 2008, 40, 2023-2039.	2.8	250
52	Bcl-2-associated athanogene-1 (BAG-1): A transcriptional regulator mediating chondrocyte survival and differentiation during endochondral ossification. Bone, 2008, 42, 113-128.	2.9	13
53	ERK and the F-box Protein $\beta$ -TRCP Target STAT1 for Degradation. Journal of Biological Chemistry, 2008, 283, 16077-16083.	3.4	41
54	Urocortin prevents mitochondrial permeability transition in response to reperfusion injury indirectly by reducing oxidative stress. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H928-H938.	3.2	60

#	ARTICLE	IF	CITATIONS
55	Role of the JAK-STAT pathway in myocardial injury. <i>Trends in Molecular Medicine</i> , 2007, 13, 82-89.	6.7	137
56	STAT1 regulates p73-mediated Bax gene expression. <i>FEBS Letters</i> , 2007, 581, 1217-1226.	2.8	21
57	Free radical scavenging inhibits STAT phosphorylation following in vivo ischemia/reperfusion injury. <i>FASEB Journal</i> , 2006, 20, 2115-2117.	0.5	66
58	The Transcriptional Coactivator p300 Plays a Critical Role in the Hypertrophic and Protective Pathways Induced by Phenylephrine in Cardiac Cells but Is Specific to the Hypertrophic Effect of Urocortin. <i>ChemBioChem</i> , 2005, 6, 162-170.	2.6	40
59	STAT-1 facilitates the ATM activated checkpoint pathway following DNA damage. <i>Journal of Cell Science</i> , 2005, 118, 1629-1639.	2.0	54
60	Cardioprotection mediated by urocortin is dependent upon PKC $\mu$ activation. <i>FASEB Journal</i> , 2005, 19, 1-18.	0.5	44
61	Hypertrophic effects of urocortin homologous peptides are mediated via activation of the Akt pathway. <i>Biochemical and Biophysical Research Communications</i> , 2005, 328, 442-448.	2.1	39
62	BAG-1: a multi-functional pro-survival molecule. <i>International Journal of Biochemistry and Cell Biology</i> , 2005, 37, 251-259.	2.8	65
63	BAG-1 in carcinogenesis. <i>Expert Reviews in Molecular Medicine</i> , 2004, 6, 1-15.	3.9	31
64	PIAS-1 Is a Checkpoint Regulator Which Affects Exit from G1 and G2 by Sumoylation of p73. <i>Molecular and Cellular Biology</i> , 2004, 24, 10593-10610.	2.3	77
65	BAG-1 Proteins Protect Cardiac Myocytes from Simulated Ischemia/Reperfusion-induced Apoptosis via an Alternate Mechanism of Cell Survival Independent of the Proteasome. <i>Journal of Biological Chemistry</i> , 2004, 279, 20723-20728.	3.4	48
66	Epigallocatechin-3-gallate inhibits STAT1 activation and protects cardiac myocytes from ischemia/reperfusion-induced apoptosis. <i>FASEB Journal</i> , 2004, 18, 1621-1623.	0.5	168
67	STAT-1 Interacts with p53 to Enhance DNA Damage-induced Apoptosis. <i>Journal of Biological Chemistry</i> , 2004, 279, 5811-5820.	3.4	200
68	The cardioprotective effect of urocortin during ischaemia/reperfusion involves the prevention of mitochondrial damage. <i>Biochemical and Biophysical Research Communications</i> , 2004, 321, 479-486.	2.1	26
69	BAG-1: a multifunctional regulator of cell growth and survival. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2003, 1603, 83-98.	7.4	68
70	The retinoblastoma protein interacts with Bag-1 in human colonic adenoma and carcinoma derived cell lines. <i>International Journal of Cancer</i> , 2003, 106, 364-371.	5.1	26
71	The nuclear BAG-1 isoform, BAG-1L, enhances oestrogen-dependent transcription. <i>Oncogene</i> , 2003, 22, 4973-4982.	5.9	63
72	Urocortin protects cardiac myocytes from ischemia/reperfusion injury by attenuating calcium insensitive phospholipase A2 gene expression. <i>FASEB Journal</i> , 2003, 17, 2313-2315.	0.5	49

#	ARTICLE	IF	CITATIONS
73	BAG-1 prevents stress-induced long-term growth inhibition in breast cancer cells via a chaperone-dependent pathway. <i>Cancer Research</i> , 2003, 63, 4150-7.	0.9	47
74	The C-terminal activation domain of the STAT1 transcription enhances ischemia/reperfusion-induced apoptosis in cardiac myocytes. <i>FASEB Journal</i> , 2002, 16, 1-17.	0.5	51
75	Oligodeoxynucleotide Targeted to the $\beta$ Gene Inhibits $\beta$ Integrin Synthesis, Impairs Osteoclast Function, and Activates Intracellular Signals to Apoptosis. <i>Journal of Bone and Mineral Research</i> , 1999, 14, 1867-1879.	2.8	26